We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron Reports Positive Data on Rare Blood Disorder Drug
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced top-line data from a mid-stage study on pipeline candidate pozelimab (REGN3918) for the treatment of rare blood disorder — paroxysmal nocturnal hemoglobinuria (PNH).
Pozelimab, an investigational, fully-human monoclonal antibody, is designed to block complement factor C5 and prevent the destruction of red blood cells (hemolysis) that cause the symptoms of PNH and other diseases mediated by complement pathway activity.
The results showed that pozelimab reduced the abnormal destruction of red blood cells (known as "hemolysis), with patients in the initial cohort achieving normal levels of a blood biomarker of elevated hemolysis called lactate dehydrogenase (LDH). Patients in the trial initially received a 30-mg/kg IV loading dose of pozelimab, followed by weekly 800-mg subcutaneous injections. All 6 patients in the initial treatment cohort treated with pozelimab experienced rapid and sustained reductions in LDH up to week 8.
No adverse events were serious or led to the discontinuation of the study.
The ongoing open-label, single-arm, two-part trial will enroll patients with active symptomatic PNH, who are naïve to complement inhibitors or who have not received treatment with a complement inhibitor within 6 months prior to entering the trial. It consists of two cohorts — cohort A (n=6), which is complete and has achieved its objective of dose confirmation, and cohort B (n=approx. 30), which is ongoing and will focus on further evaluating efficacy and safety in a larger PNH population.
Plans for a phase III program are underway as well.
Regeneron’s shares have lost 1.4% in the year so far against the industry’s growth of 6.2%.
The company’s lead drug, Eylea, continues to drive growth. Regeneron co-developed Eylea with the HealthCare unit of Bayer AG (BAYRY - Free Report) . Meanwhile, sales of asthma drug Dupixent have been strong as well since approval. Regeneron has a collaboration agreement with Sanofi (SNY - Free Report) for this drug.
We are impressed by Regeneron’s efforts to develop its pipeline. The successful development and commercialization of other drugs will reduce its dependence on Eylea, which is likely to face stiff competition from Novartis AG’s (NVS - Free Report) Beovu.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Regeneron Reports Positive Data on Rare Blood Disorder Drug
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced top-line data from a mid-stage study on pipeline candidate pozelimab (REGN3918) for the treatment of rare blood disorder — paroxysmal nocturnal hemoglobinuria (PNH).
Pozelimab, an investigational, fully-human monoclonal antibody, is designed to block complement factor C5 and prevent the destruction of red blood cells (hemolysis) that cause the symptoms of PNH and other diseases mediated by complement pathway activity.
The results showed that pozelimab reduced the abnormal destruction of red blood cells (known as "hemolysis), with patients in the initial cohort achieving normal levels of a blood biomarker of elevated hemolysis called lactate dehydrogenase (LDH). Patients in the trial initially received a 30-mg/kg IV loading dose of pozelimab, followed by weekly 800-mg subcutaneous injections. All 6 patients in the initial treatment cohort treated with pozelimab experienced rapid and sustained reductions in LDH up to week 8.
No adverse events were serious or led to the discontinuation of the study.
The ongoing open-label, single-arm, two-part trial will enroll patients with active symptomatic PNH, who are naïve to complement inhibitors or who have not received treatment with a complement inhibitor within 6 months prior to entering the trial. It consists of two cohorts — cohort A (n=6), which is complete and has achieved its objective of dose confirmation, and cohort B (n=approx. 30), which is ongoing and will focus on further evaluating efficacy and safety in a larger PNH population.
Plans for a phase III program are underway as well.
Regeneron’s shares have lost 1.4% in the year so far against the industry’s growth of 6.2%.
The company’s lead drug, Eylea, continues to drive growth. Regeneron co-developed Eylea with the HealthCare unit of Bayer AG (BAYRY - Free Report) . Meanwhile, sales of asthma drug Dupixent have been strong as well since approval. Regeneron has a collaboration agreement with Sanofi (SNY - Free Report) for this drug.
We are impressed by Regeneron’s efforts to develop its pipeline. The successful development and commercialization of other drugs will reduce its dependence on Eylea, which is likely to face stiff competition from Novartis AG’s (NVS - Free Report) Beovu.
Regeneron currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>